C. Ciprofloxacin in peritonitis associated with continuous ambulatory peritoneal dialysis (CAPD)
|
|
- Cordelia Thompson
- 5 years ago
- Views:
Transcription
1 C. Ciprofloxacin in peritonitis associated with continuous ambulatory peritoneal dialysis (CAPD)
2 Journal of Antimicrobial Chemotherapy (90) 6, Suppl. F, 63-7 A comparison between oral ciprofloxacin and intraperitoneal vancomycin and netilmicin in CAPD peritonitis J. S. Tapson', K. E. OTT*, J. C. George", E. StansfieW*, A. J. Bint* and M. K. Ward" Departments of'nephrology and b Clinical Microbiology, Royal Victoria Infirmary, Newcastle-upon-Tyne, Tyne and Wear NE4LP, UK This report describes a prospective, randomized comparison of oral ciprofloxacin and intraperitoneal vancomycin/netilmicin in the treatment of 50 consecutive episodes of CAPD peritonitis in 35 patients. Successful cure of peritonitis was achieved in 76% of subjects taking oral ciprofloxacin and 7% of those given intraperitoneal antibiotics. Satisfactory concentrations of ciprofloxacin in dialysate were achieved in all patients. Failure of ciprofloxacin was due to persistence of an isolate of intermediate sensitivity (), to persistence with acquisition of resistance (), and to relapse/reinfection in the remaining four cases (with resistant or moderately sensitive strains in three cases). Ciprofloxacin was well tolerated in the majority of cases. A significant rise in serum creatinine was noted in almost all patients taking oral ciprofloxacin. The advantages of oral drug administration indicate that oral ciprofloxacin is the preferred first-line treatment of CAPD-associated peritonitis. Introduction Peritonitis remains the major complication of continuous ambulatory peritoneal dialysis (CAPD) despite improved technology. Many different antimicrobial agents have been used to treat CAPD peritonitis. Antibiotics have usually been administered intraperitoneally or intravenously, and a variety of different dosing regimens have been suggested. No single regimen has been shown to be the most efficacious in clinical trials. There have been few reports of treatment with oral antibiotics (Knight et al., 8; Drew et al., 84; Searle & Raman, 85). Indeed a recent report from an ad hoc Advisory Committee on Peritonitis Management fails to recommend oral antimicrobial therapy for this complication (Keane et al., 89). However, phannacokinetic studies of oral treatment with the quinolone antibiotic ciprofloxacin have shown that peritoneal dialysate ciprofloxacin levels can be maintained above the MIC of most species causing CAPD peritonitis (Fleming et al., 87). A subsequent study demonstrated that a single course of oral ciprofloxacin was 76% successful as a first-line treatment for CAPD peritonitis caused by a wide range of organisms (Fleming et al., 90). However, studies comparing oral ciprofloxacin with traditional intraperitoneal antibiotic regimens have been lacking. If effective, oral treatment would offer the following potential advantages: simple drug administration, outpatient management, early commencement of home treatment, the avoidance of dialysate contamination and cost reduction. We have therefore performed a prospective, randomized study comparing the use of oral ciprofloxacin /90/6F $0.00/0 90 The British Society for Antimicrobial Chemotherapy
3 64 J. S. Tapson et al. with intraperitoneal vancomycin and/or netilmicin in 50 consecutive episodes of CAPD peritonitis presenting to the Renal Unit at the Royal Victoria Infirmary, Newcastleupon-Tyne. Patients and methods During the period from December 88 until March 90, 50 consecutive episodes of CAPD peritonitis (dialysate white cell counts greater than 00///, with or without other symptoms and signs) were entered into the study. All patients gave informed consent. Exclusion criteria were the presence of vomiting, chronic liver disease, a history of convulsions or allergy to compounds of the nalidixic acid/quinolone class, pregnancy or co-existing antibiotic therapy. No patient entered was taking theophylline and any oral medication containing magnesium or aluminium compounds was stopped. The 50 episodes of peritonitis occurred in 35 patients (0 males, 5 females); 5 patients had only one episode, seven had two episodes, two had three episodes and one lady hadfiveepisodes. No individual had experienced peritonitis during the 8 days before study entry. After the diagnosis of peritonitis was established each patient performed three two-litre dialysate 'flush' exchanges followed by four two-litre exchanges every day during the period of study. The patients were randomized using a predetermined randomization code, generated by a computer program, in blocks of ten subjects, five to each treatment regimen. Patients received ten days treatment with either oral ciprofloxacin or intraperitoneal vancomycin and/or netilmicin. Patients treated with ciprofloxacin took the antibiotic orally at the time of each dialysate exchange. Patients whose body weight was > 70 kg took 500 mg qds (n = 7) whilst those who weighed < 70 kg took 50 mg qds (n = 8). Patients randomized to receive intraperitoneal antibiotic therapy commenced treatment with vancomycin 30 mg added to each two-litre dialysate bag, and netilmicin 30 mg in alternate bags (unless Gram stain of the presenting dialysate indicated appropriateness of monotherapy). Vancomycin and netilmicin were prepared for the patients in pre-loaded syringes to ensure accurate intraperitoneal dosage. On day, all patients returned to the dialysis unit for re-assessment. A 0-ml sample of dialysate effluent was taken for microbiological evaluation from the morning drained bag. Aliquots were also taken from the morning and noon effluents for measurement of dialysate ciprofloxacin concentrations in those individuals receiving this antibiotic. Venous blood samples were taken in these patients immediately before (trough) and 90 min after (peak) the lunchtime dosage to measure plasma ciprofloxacin levels. From day, intraperitoneal antibiotics were modified in accordance with the sensitivities of isolates. Eighteen patients continued on vancomycin alone, three subjects received netilmicin alone, whilst four patients needed to continue adding both antibiotics to their dialysate bags. Patients taking oral ciprofloxacin returned to the unit on the fifth to seventh day of treatment for repeat dialysate and plasma ciprofloxacin levels (as above). All patients were reassessed after ten days of antibiotic treatment. Routine blood tests and dialysate cultures were performed on all patients. Those taking oral ciprofloxacin had dialysate and plasma concentrations re-measured (as above). Having completed ten days antibiotic treatment, patients were followed until day 8 to identify relapses. The sensitivity of isolates to the study antibiotics was routinely determined by a breakpoint method using DST agar and antibiotic concentrations of: ciprofloxacin
4 CAPD peritonitis 65 and 4mg/l, netilmicin 4 and 0mg/l, and vancomycin 8mg/l. MICs of ciprofloxacin were determined by an agar dilution method using DST agar with 5% lysed horse blood, and ciprofloxacin concentrations from O008 to 6 mg/. An inoculum of approx. KPcfu/spot was used with Staphylococcus aureus NCTC657 and Escherichia coli NCTC048 as controls. Blood and dialysate ciprofloxacin concentration were measured by a high performance liquid chromatography (HPLQ method using a Spherisorb ODSII column at 50 C with fluorescence detection and filters of 78 and 445 nm and a mobile phase of phosphoric acid and acetonitrile. The lower limit of detection was 0 mg/. Statistical analysis of pre- and post-treatment data was performed using Student's paired /-test. All means are expressed ± standard deviation. Patient characteristics Results The 5 episodes of peritonitis treated with oral ciprofloxacin occurred in patients with a mean age of 58-8 years (range 30-8) who had been on CAPD for an average of 9-6 months (range -89) and had experienced between 0 and 4 episodes of peritonitis during the previous year. There were no significant differences in these characteristics among the patients who received intraperitoneal antibiotics: 5 peritonitis episodes, mean age 55-3 years (range 30-76), time on CAPD 4-8 months (range -93) and 0-3 episodes of peritonitis during the previous year. Similarly, both groups of patients had an even distribution of associated diseases (angina pectoris, hypertension, CVA, etc) and concomitant appropriate medications. Clinical presentation Ah peritonitis episodes were associated with a cloudy dialysate effluent. In the ciprofloxacin group, 5 patients had abdominal pain, three had diarrhoea, two had nausea, one had chills and one patient had a fever. In the vancomycin/netilmicin group, individuals had abdominal discomfort, three had diarrhoea, one had nausea and six were pyrexial. Initial investigations There were no significant differences in haematology and biochemistry results at presentation between the two groups of patients (Table I). Dialysate white cell counts were similar in both groups. Table II documents the causative organisms isolated from the dialysate effluents at presentation from both groups of patients. Forty-two of these isolates were tested for sensitivity to ciprofloxacin by the breakpoint method: 88% were sensitive; 7% were moderately sensitive (E.coli, ; coagulase-negative staphylococcus ) and 5% were resistant (non-haemolytic streptococcus, ; coagulase-negative staphylococcus, ). Subsequent investigations Ciprofloxacin group. Table III shows the paired results of haematology and biochemistry before and after ciprofloxacin treatment. Significant increases in serum
5 66 J. S. Tapsoo et at Table L Initial investigations Ciprofloxacin group Vancomycin/ nctilmicin group Haemoglobin (g/dl) WCC(x 07) Platelets (x 0 9 /!) Na (mmol/) K (mmol/) Ca (mmol/) Urea (mmol/) Creatinine (/anol/) Urate (mmol/) Aspflrtntc trflp"" ''n!i«(u/) Alkaline phosphatase (u/) Dialysate WCC/ul 9- ±-7 9- ± ± ±4-4- ±-0-3±0-9 ± ± ±(M) 4-8 ± ± ± ±-l 0-3 ± ± ±3-4- ± ±0-8 ± ± ± ± ± ±344 creatinine, urate and aspartate transaminase were noted after treatment. The rise in serum creatinine was particularly marked with a mean increment of 0-6/imol/l. Vancomycin/netilmicin group. Table IV shows the paired data for haematology and biochemistry before and after intraperitoneal antibiotics. Only serum urate changed significantly after treatment Clinical response Nineteen of the 5 peritonitis episodes were finally cured by ciprofloxacin. In two episodes ciprofloxacin failed to resolve the peritonitis. After satisfactory response, a further four patients subsequently relapsed. Eighteen of the 5 episodes treated with intraperitoneal antibiotics were finally cured. In the remaining seven patients, peritonitis resolved only to relapse after antibiotic therapy had finished. Table II. Isolates from dialysate at presentation Ciprofloxacin group Vancomycin/ nctilmicin group Coagulase-negative staphylococus Staph aureus Micrococcus Diphtheroid Streptococcus sp. Coliform E. coli Klebsiella sp. Pseudomonas sp. No growth
6 CAPD peritonitis 67 Table HI. Investigations before and after treatment with ciprofloxacin No. of patients Before After Haemoglobin (g/dl) WCC(x 07) Platelets (x 07) Na (mmol/) K (mmol/) Ca (mmol/) Urea (mmol/) Creatinine Qnnol/) Urate (mmol/) Aspartate transaminasc (u/) Alkaline phosphatase P<<HK), h P <OO. Bacteriological response O ' * -6* Ciprofloxacin group. Thirteen of the 5 peritonitis episodes were successfully treated with ciprofloxacin with bacteriologically proven eradication of the isolated organism. In six other successful clinical responses to oral ciprofloxacin bacteriological response was indeterminate because of a failure to obtain a positive culture from pre-treatment dialysate effluent. Six episodes of peritonitis were treatment failures on ciprofloxacin. In two cases, both due to coagulase-negative staphylococci, the organisms persisted despite treatment. One of these infections was due to a strain of intermediate sensitivity to ciprofloxacin at presentation (MIC, mg/), and the other was due to two separate strains, both of which acquired resistance to the antibiotic by day 5 of treatment (MIC increased from 0-5 to mg/). In two other cases, peritonitis returned following Table TV. Investigations before and after vancomycin/netilmicin Haemoglobin (g/dl) WCC(x 07) Platelets (x 0*/l) Na (mmol/) K (mmol/) Ca (mmol/) Urea (mmol/) Creatinine (/nnol/l) Urate (mmol/) Aftpartptr fnin<uift inax (u/) Alkaline phosphatase No. of patients Before treatment After l(k>i * with 'P<O00\.
7 68 J. S. Tapson et al. successful eradication of a ciprofloxacin sensitive organism or a ciprofloxacin intermediately sensitive organism after completion of ten days treatment. One patient redeveloped a cloudy bag on day, owing to recurrence of infection by the original diphtheroid, which remained moderately sensitive to the antibiotic (MIC = mg/). The other patient experienced a clinical relapse on day 4 due to recurrence of a coagulase-negative staphylococcus which maintained ciprofloxacin sensitivity. Two other cases relapsed after successful eradication of ciprofloxacin-sensitive S. aureus isolates with re-infection by a different organism (a coagulase-negative staphylococcus, resistant to ciprofloxacin, isolated in both cases, on days 7 and 0, respectively). Vancomycin/netilmicin group. Fifteen of the 5 peritonitis episodes were successfully treated with intraperitoneal antibiotics with eradication of the presenting isolates. In three other successful clinical responses bacteriological evaluation was indeterminate because of negative culture results from the presenting cloudy dialysate effluent Seven episodes of peritonitis were treatment failures on the vancomycin/netilmicin regimen. In all cases clinical resolution of peritonitis was followed by recurrence of cloudy bags after completion of the ten days intraperitoneal antibiotics. In two of these cases bacteriological response was indeterminate either because of a negative culture at presentation or from the recurrent cloudy bag (which occurred on days and 3 respectively). In the remaining five episodes of peritonitis, bacteriological eradication occurred after ten days intraperitoneal vancomycin. Recurrence of the vancomycinsensitive staphylococcus occurred in each case (on days, 5,, 5 and 7 respectively. Ciprofloxacin concentrations Figure shows the mean trough and peak plasma ciprofloxacin concentrations for the 8 individuals taking 50mgqds and the seven individuals taking 500mgqds. Figure shows dialysate ciprofloxacin concentrations in the two groups of patients taking this medication. Adverse effects The treatment was well tolerated. No patient treated with intraperitoneal antibiotics developed adverse reactions. Four patients on ciprofloxacin had minimal side effects: nausea (3), lethargy (), anorexia () and myalgia (). In only one of these patients were high plasma ciprofloxacin levels present (mean trough value 9-8 mg/, peak value -7 mg/). This patient took 500 mg ciprofloxacin qds. Discussion The intraperitoneal use of vancomycin with an aminoglycoside continues to be recommended for first-line treatment of peritonitis complicating CAPD (Spencer & Fenton, 84; Keane et al., 89). The use of such antibiotics complicates treatment regimens. Many patients find it difficult to add antibiotics to their CAPD bags and admission to hospital for training and/or treatment is occasionally necessary. Instillation of antibiotics may result in contamination of dialysate. In addition, although aminoglycoside ototoxicity after a single ten-day course is rare, repeated treatment may be required for
8 CAPD peritonitis 69 T 0 I a. (7) (7) T P / \ (5) I I T P' 6 (i4) ( ' 4) T 'C500 #C50 P 0 Doys Figure. Plasma ciprofloxacin concentrations. T, trough; P, peak; CSOO, 300mgqds dotage; CS0, 50 mg qdi dosage; ( ) number of patients in group. [mg/d 0 E 6 8 Mo i 4 &oprof (5 _ (6) ( i / (6) (5) (5) i i 6 (4)»C500 Flgnre. Dialytate dprofloxacin concentrations. CSOO, SOOmgqds dote; CS0, S0mgqds dose; ( ) number of patienu in group. Days (4) l 0
9 70 J. S. Tapson et al recurrent peritonitis, and the dangers of ototoxicity increase. Finally, the use of intraperitoneal antibiotics is expensive. For these reasons the treatment of CAPD peritonitis would be greatly simplified by an oral antibiotic active against the commonly encountered pathogens that is able to reach bactericidal concentrations rapidly in the peritoneal dialysate. Previous reports that describe oral therapy have used cephalosporins (Knight et al., 8; Drew et al., 84; Searle & Raman, 85). Ciprofloxacin is a bactericidal antimicrobial agent. It has a broad spectrum of activity including Gram-negative and certain Gram-positive organisms, being particularly active against members of the Enterobacteriaceae and Pseudomonas species. In addition cross-resistance between ciprofloxacin and the /?- lactams and aminoglycosides is not a problem. Preliminary studies have demonstrated that therapeutic concentrations of ciprofloxacin may be achievable in the peritoneal dialysis fluid after oral administration to patients undergoing CAPD (Shalit et al., 86). A subsequent study demonstrated the efficacy of oral ciprofloxacin in treating 33 unselected episodes of CAPD peritonitis (Fleming et al., 90). Our prospective, randomized comparison of oral ciprofloxacin and intraperitoneal vancomycin/netilmicin confirms that this oral antibiotic is a useful alternative in the management of bacterial peritonitis in CAPD patients. Overall a single course of oral ciprofloxacin was 76% successful as first-line treatment in 5 episodes of CAPD peritonitis. This compares with a success rate of 7% for 5 episodes in a comparable group of individuals treated with intraperitoneal antibiotics. The use of intraperitoneal antibiotics resulted in a clinical cure of all episodes of peritonitis by day 0 of treatment with clear dialysate effluent in all cases. Failure of therapy was due to relapse after discontinuation of antibiotics. Clear dialysate effluent was achieved after ten days oral ciprofloxacin treatment in 3 patients. However, four of these subjects subsequently redeveloped cloudy dialysate after oral treatment had been discontinued. The return of peritonitis was due to recurrence/re-infection by resistant or moderately sensitive strains in three of these cases. Dialysate ciprofloxacin levels were maintained above mg/l (which exceeded the MIC for 95% of the original isolates causing peritonitis in this study) in all but three patients. These three patients achieved a clinical cure. In the six patients who were treatment failures, dialysate ciprofloxacin concentrations exceeded -7 mg/ in all cases. Treatment failure of ciprofloxacin was due to organisms with reduced sensitivity in all but one case, rather than an inability to achieve satisfactory antibiotic levels in peritoneal dialysate. Ciprofloxacin was well tolerated in most cases. In only one patient were adverse effects felt to be a consequence of high plasma ciprofloxacin levels. A significant rise in plasma urate levels was noted in both treatment groups. Elevation of plasma transaminases during ciprofloxacin has been reported in some cases previously (Arcieri et al., 86). In none of our patients, however, did this serum enzyme level rise out of the normal reference range for our laboratory. A rise in serum creatinine has also been previously reported in a few patients (Arcieri et al., 86). Seventeen of the patients taking ciprofloxacin, for whom paired data were available, showed a rise in serum creatinine. The explanation of this change remains uncertain, but the effect was transient, and return to pre-treatment levels occurred in all patients at follow up. Oral ciprofloxacin treatment is also cost-effective. At present prices (April 90), ten days treatment with ciprofloxacin 50mgqds costs 6.7 (exclusive of VAT). This compared with 3.9 for vancomycin prepared in pre-loaded syringes, taken from
10 CAPD peritonitis 7 3x5OOmg vials, and 7.4 for netilmicin in pre-loaded syringes, taken from x50mg vials. Acknowledgements We are grateful to Dr L. O. White, Southmead Hospital, Bristol for performing ciprofloxacin assays in the early part of the study. We also thank the nursing staff of the Regular Dialysis Unit, Royal Victoria Infirmary for their help and co-operation with this study, and Miss C. Lee for secretarial assistance. References Arcieri, G., August, R., Becker, N., Doyle, C, Griffith, E., Gruenwaldt, G. et al. (86). Clinical experience with ciprofloxacin in the USA. European Journal of Clinical Microbiology 5, 0-5. Drew, P. J., CaseweU, M. W., Desai, N., Houang, E. T., Simpson, C. N. & Marsh, F. P. (84). Cephalexin for the oral treatment of CAPD peritonitis. Journal of Antimicrobial Chemotherapy 3, Fleming, L. W., Moreland, T. A., Scott, A. C, Stewart, W. K. & White, L. O. (87). Ciprofloxacin in plasma and peritoneal dialysate after oral therapy in patients on continuous ambulatory peritoneal dialysis. Journal of Antimicrobial Chemotherapy, Fleming, L. W., Phillips, G., Stewart, W. K. & Scott, A. C. (90). Oral ciprofloxacin in the treatment of peritonitis in patients on continuous ambulatory peritoneal dialysis. Journal of Antimicrobial Chemotherapy 5, Keane, W. F., Dale Everett, E., Fine, R. N., Golper, T. A., Vas, S., Peterson, P. K. et al. (89). Continuous ambulatory peritoneal dialysis (CAPD) peritonitis treatment recommendations: 89 update. Peritoneal Dialysis International 9, Knight, K. R., Polak, A., Crump, J. & Maskell, R. (8). Laboratory diagnosis and oral treatment of CAPD peritonitis. Lancet ii, Sanders, C. C, Sanders, W. E. & Goering, R. V. (87). Overview of precunical studies with ciprofloxacin. American Journal of Medicine 8, Suppl. 4A, -. Earle, M. & Raman, G. V. (85). Oral treatment of peritonitis complicating continuous ambulatory peritoneal dialysis. Clinical Nephrology 3, 4-4. Shalit, I., Greenwood, R. B., Marks, M. I., Pederson, J. A. & Frederick, D. L. (86). Pharmacoldnetics of single-dose oral ciprofloxacin in patients undergoing chronic ambulatory peritoneal dialysis. Antimicrobial Agents and Chemotherapy 30, 5-6. Spencer, R. C. & Fenton, P. A. (84). Infective complications of peritoneal dialysis. Journal of Hospital Infection 5,
Randomized Controlled Trial on Adjunctive Lavage for Severe Peritoneal Dialysis- Related Peritonitis
Randomized Controlled Trial on Adjunctive Lavage for Severe Peritoneal Dialysis- Related Peritonitis Steve SM Wong Alice Ho Miu Ling Nethersole Hospital Background PD peritonitis is a major cause of PD
More informationTo guide safe and appropriate selection of antibiotic therapy for Peritoneal Dialysis patients.
Nephrology Directorate Subject: Objective: Prepared by: Aintree Antibiotic Guidelines for Peritoneal Dialysis (PD): Catheter Insertion, and the Diagnosis and Treatment of PD Peritonitis and Exit-Site Infections.
More informationStanding Orders for the Treatment of Outpatient Peritonitis
Standing Orders for the Treatment of Outpatient Peritonitis 1. Definition of Peritonitis: a. Cloudy effluent. b. WBC > 100 cells/mm3 with >50% polymorphonuclear (PMN) cells with minimum 2 hour dwell. c.
More informationStanding Orders for the Treatment of Outpatient Peritonitis
Standing Orders for the Treatment of Outpatient Peritonitis 1. Definition of Peritonitis: a. Cloudy effluent. b. WBC > 100 cells/mm3 with >50% polymorphonuclear (PMN) cells with minimum 2 hour dwell. c.
More informationDiagnosis: Presenting signs and Symptoms include:
PERITONITIS TREATMENT PROTOCOL CARI - Caring for Australasians with Renal Impairment - CARI Guidelines complete list ISPD Guidelines: http://www.ispd.org/lang-en/treatmentguidelines/guidelines Objective
More informationTreatment of peritonitis in patients receiving peritoneal dialysis Antibiotic Guidelines. Contents
Treatment of peritonitis in patients receiving Antibiotic Guidelines Classification: Clinical Guideline Lead Author: Jude Allen (Pharmacist) Additional author(s): Dr David Lewis, Dr Dimitrios Poulikakos,
More informationTREATMENT OF PERITONEAL DIALYSIS (PD) RELATED PERITONITIS. General Principles
WA HOME DIALYSIS PROGRAM (WAHDIP) GUIDELINES General Principles 1. PD related peritonitis is an EMERGENCY early empiric treatment followed by close review is essential 2. When culture results and sensitivities
More informationPERITONEAL DIALYSIS PERITONITIS - DIAGNOSIS AND TREATMENT
PERITONEAL DIALYSIS PERITONITIS - DIAGNOSIS AND TREATMENT Renal, Respiratory, Cardiac and Vascular CMG 1 BACKGROUND In Leicester the rate of PD peritonitis is on average one episode in 19 months PD treatment.
More informationIntravenous Antibiotic Therapy Information Leaflet
Scottish Adult Cystic Fibrosis Service Ninewells Hospital Dundee Intravenous Antibiotic Therapy Information Leaflet February 2008 Intravenous antibiotic therapy in cystic fibrosis Patients with cystic
More informationThese recommendations were approved for use by the Pharmaceutical and Therapeutics Committee, RCWMCH on 1 February 2017.
Antibiotic regimens for suspected hospital-acquired infection (HAI) outside the Paediatric Intensive Care Unit at Red Cross War Memorial Children s Hospital (RCWMCH) Lead author: Brian Eley Contributing
More informationPatients. Excludes paediatrics, neonates.
Full title of guideline Author Division & Speciality Scope Gentamicin Prescribing Guideline For Adult Patients Annette Clarkson, Specialist Clinical Pharmacist Antimicrobials and Infection Control All
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Cephacare flavour 50 mg tablets for cats and dogs. Excipients: For a full list of excipients, see section 6.1.
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Cephacare flavour 50 mg tablets for cats and dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Active
More informationScottish Medicines Consortium
Scottish Medicines Consortium tigecycline 50mg vial of powder for intravenous infusion (Tygacil ) (277/06) Wyeth 9 June 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationProtocol for exit-site care and treatment of exit-site infections in peritoneal dialysis CONTROLLED DOCUMENT
CONTROLLED DOCUMENT Protocol for exit-site care and treatment of exit-site infections in peritoneal dialysis CATEGORY: CLASSIFICATION: PURPOSE Controlled Document Number: Guideline Clinical The purpose
More informationAppropriate Antimicrobial Therapy for Treatment of
Appropriate Antimicrobial Therapy for Treatment of Staphylococcus aureus infections ( MRSA ) By : A. Bojdi MD Assistant Professor Inf. Dis. Dep. Imam Reza Hosp. MUMS Antibiotics Still Miracle Drugs Paul
More informationPharmacology Week 6 ANTIMICROBIAL AGENTS
Pharmacology Week 6 ANTIMICROBIAL AGENTS Mechanisms of antimicrobial action Mechanisms of antimicrobial action Bacteriostatic - Slow or stop bacterial growth, needs an immune system to finish off the microbe
More informationGUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS
Version 3.1 GUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS Date ratified June 2008 Updated March 2009 Review date June 2010 Ratified by Authors Consultation Evidence base Changes
More informationCefazolin vs. Antistaphyloccal Penicillins: The Great Debate
Cefazolin vs. Antistaphyloccal Penicillins: The Great Debate Annie Heble, PharmD PGY2 Pediatric Pharmacy Resident Children s Hospital Colorado Microbiology Rounds March 22, 2017 Image Source: Buck cartoons
More informationAPPROVED PACKAGE INSERT. Each capsule contains clindamycin hydrochloride equivalent to 150 mg clindamycin base.
APPROVED PACKAGE INSERT SCHEDULING STATUS: S4 PROPRIETARY NAMEAND DOSAGE FORM: DALACIN C TM 150 mg (Capsules) COMPOSITION: Each capsule contains clindamycin hydrochloride equivalent to 150 mg clindamycin
More informationEmpiric antimicrobial use in the treatment of dialysis related infections in RIPAS Hospital
Original Article Brunei Int Med J. 2013; 9 (6): 372-377 Empiric antimicrobial use in the treatment of dialysis related infections in RIPAS Hospital Lah Kheng CHUA, Department of Pharmacy, RIPAS Hospital,
More informationSafe Patient Care Keeping our Residents Safe Use Standard Precautions for ALL Residents at ALL times
Safe Patient Care Keeping our Residents Safe 2016 Use Standard Precautions for ALL Residents at ALL times #safepatientcare Do bugs need drugs? Dr Deirdre O Brien Consultant Microbiologist Mercy University
More informationBacterial skin and soft tissues infections (SSTI) are one of the most common 1. infections among different age groups
Bacterial skin and soft tissues infections (SSTI) are one of the most common 1 infections among different age groups Gram-positive bacteria are the most frequently isolated pathogens from SSTI, with a
More informationInteractive session: adapting to antibiogram. Thong Phe Heng Vengchhun Felix Leclerc Erika Vlieghe
Interactive session: adapting to antibiogram Thong Phe Heng Vengchhun Felix Leclerc Erika Vlieghe Case 1 63 y old woman Dx: urosepsis? After 2 d: intermediate result: Gram-negative bacilli Empiric antibiotic
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. 10. Treatment of peritoneal dialysis associated fungal peritonitis
10. Treatment of peritoneal dialysis associated fungal peritonitis Date written: February 2003 Final submission: July 2004 Guidelines (Include recommendations based on level I or II evidence) The use of
More informationTherios 300 mg and 750 mg Palatable Tablets for Dogs
Ceva Animal Health Ltd Telephone: 01494 781510 Website: www.ceva.com Email: cevauk@ceva.com Therios 300 mg and 750 mg Palatable Tablets for Dogs Species: Therapeutic indication: Active ingredient: Product:
More informationAppropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
More informationAntibiotic Prophylaxis Update
Antibiotic Prophylaxis Update Choosing Surgical Antimicrobial Prophylaxis Peri-Procedural Administration Surgical Prophylaxis and AMS at Epworth HealthCare Mr Glenn Valoppi Dr Trisha Peel Dr Joseph Doyle
More information1 TRADE NAME OF THE MEDICINAL PRODUCT. Gentamicin Paediatric 20mg/2ml Solution for Injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
1 TRADE NAME OF THE MEDICINAL PRODUCT Gentamicin Paediatric 20mg/2ml Solution for Injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 2ml contains 20mg of Gentamicin as Gentamicin Sulfate Excipient
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT RONAXAN 20mg Tablet 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Active substance : Doxycycline (as doxycycline
More informationIntroduction to Pharmacokinetics and Pharmacodynamics
Introduction to Pharmacokinetics and Pharmacodynamics Diane M. Cappelletty, Pharm.D. Assistant Professor of Pharmacy Practice Wayne State University August, 2001 Vocabulary Clearance Renal elimination:
More informationInfection Comments First Line Agents Penicillin Allergy History of multiresistant. line treatment: persist for >7 days they may be
Gastrointestinal Infections Infection Comments First Line Agents Penicillin Allergy History of multiresistant Campylobacter Antibiotics not recommended. Erythromycin 250mg PO 6 Alternative to first N/A
More informationA retrospective analysis of urine culture results issued by the microbiology department, Teaching Hospital, Karapitiya
A retrospective analysis of urine culture results issued by the microbiology department, Teaching Hospital, Karapitiya LU Edirisinghe 1, D Vidanagama 2 1 Senior Registrar in Medicine, 2 Consultant Microbiologist,
More informationInappropriate Use of Antibiotics and Clostridium difficile Infection. Jocelyn Srigley, MD, FRCPC November 1, 2012
Inappropriate Use of Antibiotics and Clostridium difficile Infection Jocelyn Srigley, MD, FRCPC November 1, 2012 Financial Disclosures } No conflicts of interest } The study was supported by a Hamilton
More informationmoxifloxacin intravenous, 400mg/250mL, solution for infusion (Avelox ) SMC No. (650/10) Bayer Schering
moxifloxacin intravenous, 400mg/250mL, solution for infusion (Avelox ) SMC No. (650/10) Bayer Schering 05 November 2010 The Scottish Medicines Consortium (SMC) has completed its assessment of the above
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #407: Appropriate Treatment of Methicillin-Susceptible Staphylococcus Aureus (MSSA) Bacteremia National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES:
More informationJerome J Schentag, Pharm D
Clinical Pharmacy and Optimization of Antibiotic Usage: How to Use what you have Learned in Pharmacokinetics and Pharmacodynamics of Antibiotics Jerome J Schentag, Pharm D Presented at UCL on Thursday
More informationSt George/Sutherland Hospitals And Health Services (SGSHHS)
PERITONEAL DIALYSIS (PD) PERITONITIS MANAGEMENT AND TREATMENT Cross References (including NSW Health/ SESLHD policy directives) Medication Handling in NSW Public Health Facilities; NSW Health PD2013_043
More informationGuideline for the diagnosis and treatment of PD peritonitis and exit site infections in adults
Full title of guideline Author Division & Speciality Scope (Target audience, state if Trust wide) Explicit definition of patient group to which it applies (e.g. inclusion and exclusion criteria, diagnosis)
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
Antibiotic treatment and monitoring for suspected or confirmed early-onset neonatal infection bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to
More informationSimilar to Penicillins: -Chemically. -Mechanism of action. -Toxicity.
Similar to Penicillins: -Chemically. -Mechanism of action. -Toxicity. Cephalosporins are divided into Generations: -First generation have better activity against gram positive organisms. -Later compounds
More information13. Treatment of peritoneal dialysis-associated peritonitis in adults
13. Treatment of peritoneal dialysis-associated peritonitis in adults Date written: February 2003 Final submission: July 2004 Guidelines (Include recommendations based on level I or II evidence) In peritoneal
More informationB. PACKAGE LEAFLET 1
B. PACKAGE LEAFLET 1 PACKAGE LEAFLET NICILAN 400 mg/100 mg tablets for dogs 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Inspections EMEA/CVMP/627/01-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE DEMONSTRATION OF EFFICACY
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Enrotron 50 mg/ml Solution for injection for cattle, pigs, dogs and cats
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Enrotron 50 mg/ml Solution for injection for cattle, pigs, dogs and cats 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each
More informationSpeciality: Therapeutics
Gentamicin Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Contact Name and Job Title (author) Directorate & Speciality Date of submission May 2017 Date on which
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Enrocare 50 mg/ml Solution for Injection for Cattle, Pigs, Dogs and Cats (UK, IE, FR) Floxadil 50 mg/ml Solution for Injection
More informationCentral Nervous System Infections
Central Nervous System Infections Meningitis Treatment Bacterial meningitis is a MEDICAL EMERGENCY. ANTIBIOTICS SHOULD BE STARTED AS SOON AS THE POSSIBILITY OF BACTERIAL MENINGITIS BECOMES EVIDENT, IDEALLY
More informationESBL Positive E. coli and K. pneumoneae are Emerging as Major Pathogens for Urinary Tract Infection
ESBL Positive E. coli and K. pneumoneae are Emerging as Major Pathogens for Urinary Tract Infection Muhammad Abdur Rahim*, Palash Mitra*. Tabassum Samad*. Tufayel Ahmed Chowdhury*. Mehruba Alam Ananna*.
More informationCLINICAL USE OF AMINOGLYCOSIDES AND FLUOROQUINOLONES
CLINICAL USE OF AMINOGLYCOSIDES AND FLUOROQUINOLONES Douglas Black, Pharm.D. Associate Professor School of Pharmacy University of Washington dblack@u.washington.edu THE AMINOGLYCOSIDES: 1944-1975 Drug
More informationPharmacoeconomic analysis of selected antibiotics in lower respiratory tract infection Quenzer R W, Pettit K G, Arnold R J, Kaniecki D J
Pharmacoeconomic analysis of selected antibiotics in lower respiratory tract infection Quenzer R W, Pettit K G, Arnold R J, Kaniecki D J Record Status This is a critical abstract of an economic evaluation
More informationAn evaluation of the susceptibility patterns of Gram-negative organisms isolated in cancer centres with aminoglycoside usage
Journal of Antimicrobial Chemotherapy (1991) 27, Suppl. C, 1-7 An evaluation of the susceptibility patterns of Gram-negative organisms isolated in cancer centres with aminoglycoside usage J. J. Muscato",
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Amfipen LA 100 mg/ml suspension for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance: Each ml contains:
More informationSafety of an Out-Patient Intravenous Antibiotics Programme
Safety of an Out-Patient Intravenous Antibiotics Programme Chan VL, Tang ESK, Leung WS, Wong L, Cheung PS, Chu CM Department of Medicine & Geriatrics United Christian Hospital Outpatient Parental Antimicrobial
More informationCipro for gram positive cocci in urine
Buscar... Cipro for gram positive cocci in urine 20-6-2017 Pneumonia can be generally defined as an infection of the lung parenchyma, in which consolidation of the affected part and a filling of the alveolar
More information4/3/2017 CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA DISCLOSURE LEARNING OBJECTIVES
CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA BILLIE BARTEL, PHARMD, BCCCP APRIL 7 TH, 2017 DISCLOSURE I have had no financial relationship over the past 12 months with any commercial
More informationOther Beta - lactam Antibiotics
Other Beta - lactam Antibiotics Assistant Professor Dr. Naza M. Ali Lec 5 8 Nov 2017 Lecture outlines Other beta lactam antibiotics Other inhibitors of cell wall synthesis Other beta-lactam Antibiotics
More informationThe pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens
The pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens Cellular and Molecular Pharmacology Unit Catholic University of Louvain, Brussels,
More information1. The preferred treatment option for an initial UTI episode in a 22-year-old female patient
1 Chapter 79, Self-Assessment Questions 1. The preferred treatment option for an initial UTI episode in a 22-year-old female patient with normal renal function is: A. Trimethoprim-sulfamethoxazole B. Cefuroxime
More informationReduce the risk of recurrence Clear bacterial infections fast and thoroughly
Reduce the risk of recurrence Clear bacterial infections fast and thoroughly Clearly advanced 140916_Print-Detailer_Englisch_V2_BAH-05-01-14-003_RZ.indd 1 23.09.14 16:59 In bacterial infections, bacteriological
More informationOPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS
HTIDE CONFERENCE 2018 OPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS FEDERICO PEA INSTITUTE OF CLINICAL PHARMACOLOGY DEPARTMENT OF MEDICINE, UNIVERSITY OF UDINE, ITALY SANTA
More informationMARBOCYL FD SUMMARY OF PRODUCT CHARACTERISTICS
MARBOCYL FD SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT MARBOCYL FD 1 %, powder and solvent for solution for injection, for cats and dogs. 2. QUALITATIVE AND QUANTITATIVE
More informationAntibiotic Treatment of Peritonitis
Antibiotic Treatment of Peritonitis BC Children s Hospital Step-by-Step Instructions for Parents and Allied Health Professionals February 2012 Developed by C. Prestidge, MD, J. Leechik, BSN, K. Collin,
More informationHealth Products Regulatory Authority
1 NAME OF THE VETERINARY MEDICINAL PRODUCT Genta 50 mg/ml solution for injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains: Active Substances Gentamicin sulphate equivalent to Gentamicin
More informationVOL. XXIII NO. II THE JOURNAL OF ANTIBIOTICS 559. ANTIBIOTIC 6640.* Ill
VOL. XXIII NO. II THE JOURNAL OF ANTIBIOTICS 559 ANTIBIOTIC 6640.* Ill BIOLOGICAL STUDIES WITH ANTIBIOTIC 6640, A NEW BROAD-SPECTRUM AMINOGLYCOSIDE ANTIBIOTIC J. Allan Waitz, Eugene L. Moss, Jr., Edwin
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. 8. Prophylactic antibiotics for insertion of peritoneal dialysis catheter
8. Prophylactic antibiotics for insertion of peritoneal dialysis catheter Date written: February 2003 Final submission: May 2004 Guidelines (Include recommendations based on level I or II evidence) Antibiotic
More informationConsiderations in antimicrobial prescribing Perspective: drug resistance
Considerations in antimicrobial prescribing Perspective: drug resistance Hasan MM When one compares the challenges clinicians faced a decade ago in prescribing antimicrobial agents with those of today,
More informationPharmacological Evaluation of Amikacin in Neonates
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, JUlY 1975, p. 86-90 Copyright 0 1975 American Society for Microbiology Vol. 8, No. 1 Printed in U.SA. Pharmacological Evaluation of Amikacin in Neonates JORGE B.
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Active substance: cefalexin (as cefalexin monohydrate) mg
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Cefaseptin 750 mg tablets for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One tablet contains: Active substance: cefalexin
More informationBrief reports. Decreased susceptibility to imipenem among penicillin-resistant Streptococcus pneumoniae
Journal of Antimicrobial Chemotherapy (1997) 40, 105 108 Brief reports JAC Decreased susceptibility to imipenem among penicillin-resistant Streptococcus pneumoniae Andreas Pikis a *, Jacob A. Donkersloot
More informationCork and Kerry SARI Newsletter; Vol. 2 (2), December 2006
Cork and SARI Newsletter; Vol. 2 (2), December 6 Item Type Newsletter Authors Murray, Deirdre;O'Connor, Nuala;Condon, Rosalind Download date 31/1/18 15:27:31 Link to Item http://hdl.handle.net/1147/67296
More informationMARBOCYL 10% SUMMARY OF PRODUCT CHARACTERISTICS
MARBOCYL 10% SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT MARBOCYL 10%, solution for injection for cattle and swine 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Marbofloxacin...100.0
More information2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process High Priority
Quality ID #407: Appropriate Treatment of Methicillin-Susceptible Staphylococcus Aureus (MSSA) Bacteremia National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Healthcare Associated
More informationCHAPTER:1 THE RATIONAL USE OF ANTIBIOTICS. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY
CHAPTER:1 THE RATIONAL USE OF ANTIBIOTICS BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY Antibiotics One of the most commonly used group of drugs In USA 23
More information2. Peritoneal dialysis-associated peritonitis in children
2. Peritoneal dialysis-associated peritonitis in children Date written: February 2003 Final submission: July 2004 Guidelines No recommendations possible based on Level I or II evidence Suggestions for
More informationRational management of community acquired infections
Rational management of community acquired infections Dr Tanu Singhal MD, MSc Consultant Pediatrics and Infectious Disease Kokilaben Dhirubhai Ambani Hospital, Mumbai Why is rational management needed?
More informationمادة االدوية المرحلة الثالثة م. غدير حاتم محمد
م. مادة االدوية المرحلة الثالثة م. غدير حاتم محمد 2017-2016 ANTIMICROBIAL DRUGS Antimicrobial drugs Lecture 1 Antimicrobial Drugs Chemotherapy: The use of drugs to treat a disease. Antimicrobial drugs:
More informationUSA Product Label LINCOCIN. brand of lincomycin hydrochloride tablets. brand of lincomycin hydrochloride injection, USP. For Use in Animals Only
USA Product Label http://www.vetdepot.com PHARMACIA & UPJOHN COMPANY Division of Pfizer Inc. Distributed by PFIZER INC. 235 E. 42ND ST., NEW YORK, NY, 10017 Telephone: 269-833-4000 Fax: 616-833-4077 Customer
More informationTreatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani
Treatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani 30-1-2018 1 Objectives of the lecture At the end of lecture, the students should be able to understand the following:
More informationClinical Practice Standard
Clinical Practice Standard 1-20-6-1-010 TITLE: INTRAVENOUS TO ORAL CONVERSION FOR ANTIMICROBIALS A printed copy of this document may not reflect the current, electronic version on OurNH. APPLICABILITY:
More informationStaphylex Flucloxacillin (sodium)
Staphylex Flucloxacillin (sodium) PRODUCT INFORMATION Name of the Medicine Flucloxacillin sodium is the sodium salt of 3-(2'-chloro-6'-fluorophenyl)-5-methyl-4-isoxazolylpenicillin monohydrate. Structural
More informationAntibiotics in vitro : Which properties do we need to consider for optimizing our therapeutic choice?
Antibiotics in vitro : Which properties do we need to consider for optimizing our therapeutic choice? With the support of Wallonie-Bruxelles-International 1-1 In vitro evaluation of antibiotics : the antibiogram
More informationSUMMARY OF PRODUCT CHARACTERISTICS. NUFLOR 300 mg/ml solution for injection for cattle and sheep
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT NUFLOR 300 mg/ml solution for injection for cattle and sheep 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains:
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Marbocare 20 mg/ml solution for injection for cattle and pigs (UK, IE, FR) Odimar 20 mg/ml solution for injection for cattle
More informationDuke University Hospital Guideline for Empiric Inpatient Treatment of Cancer- Related Neutropenic Fever in Adult Patients
Duke University Hospital Guideline for Empiric Inpatient Treatment of Cancer- Related Neutropenic Fever in Adult Patients PURPOSE Fever among neutropenic patients is common and a significant cause of morbidity
More informationProphylactic antibiotic timing and dosage. Dr. Sanjeev Singh AIMS, Kochi
Prophylactic antibiotic timing and dosage Dr. Sanjeev Singh AIMS, Kochi Meaning - Webster Medical Definition of prophylaxis plural pro phy lax es \-ˈlak-ˌsēz\play : measures designed to preserve health
More informationSuggestions for appropriate agents to include in routine antimicrobial susceptibility testing
Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing These suggestions are intended to indicate minimum sets of agents to test routinely in a diagnostic laboratory
More informationComparison of Gentamicin and Mupirocin in the Prevention of Exit-Site Infection and Peritonitis in Peritoneal Dialysis
Advances in Peritoneal Dialysis, Vol. 25, 2009 Anshinee Mahaldar, Michael Weisz, Pranay Kathuria Comparison of Gentamicin and Mupirocin in the Prevention of Exit-Site Infection and Peritonitis in Peritoneal
More informationCanadian Nosocomial Infection Surveillance Program 2018 SURVEILLANCE FOR HEALTHCARE ACQUIRED CEREBROSPINAL FLUID SHUNT ASSOCIATED INFECTIONS
Canadian Nosocomial Infection Surveillance Program 2018 SURVEILLANCE FOR HEALTHCARE ACQUIRED CEREBROSPINAL FLUID SHUNT ASSOCIATED INFECTIONS FINAL November 29, 2017 Working Group: Joanne Langley (Chair),
More informationDANMAP Danish Integrated Antimicrobial Resistance Monitoring and Research Programme
DANMAP Danish Integrated Antimicrobial Resistance Monitoring and Research Programme Hanne-Dorthe Emborg Department of Microbiology and Risk Assessment National Food Institute, DTU Introduction The DANMAP
More informationAntimicrobial Pharmacodynamics
Antimicrobial Pharmacodynamics November 28, 2007 George P. Allen, Pharm.D. Assistant Professor, Pharmacy Practice OSU College of Pharmacy at OHSU Objectives Become familiar with PD parameters what they
More informationPeriod of study: 12 Nov 2002 to 08 Apr 2004 (first subject s first visit to last subject s last visit)
Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website and is provided for patients and healthcare professionals to increase the transparency of Bayer's
More informationScottish Medicines Consortium
Scottish Medicines Consortium daptomycin 350mg powder for concentrate for solution for infusion (Cubicin ) Chiron Corporation Limited No. (248/06) 10 March 2006 The Scottish Medicines Consortium (SMC)
More informationIntra-Abdominal Infections. Jessica Thompson, PharmD, BCPS (AQ-ID) Infectious Diseases Pharmacy Clinical Specialist Renown Health April 19, 2018
Intra-Abdominal Infections Jessica Thompson, PharmD, BCPS (AQ-ID) Infectious Diseases Pharmacy Clinical Specialist Renown Health April 19, 2018 Select guidelines Mazuski JE, et al. The Surgical Infection
More informationPatient and Family Education How to Add Antibiotics and other Medicines to the Dialysate What do I do before I start? Gather these supplies and place them on a clean surface: Antibiotic vials and sterile
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/26062
More informationStudy population The target population for the model were hospitalised patients with cellulitis.
Comparison of linezolid with oxacillin or vancomycin in the empiric treatment of cellulitis in US hospitals Vinken A G, Li J Z, Balan D A, Rittenhouse B E, Willke R J, Goodman C Record Status This is a
More information4.5. Special precautions for use Special precautions to be taken by person administering the veterinary medicinal product to animals
1.B1. SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT AMOXYCOL Soluble Powder 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substances: Amoxicillin trihydrate 640.0
More informationGeNei TM. Antibiotic Sensitivity. Teaching Kit Manual KT Revision No.: Bangalore Genei, 2007 Bangalore Genei, 2007
GeNei Bacterial Antibiotic Sensitivity Teaching Kit Manual Cat No. New Cat No. KT68 106333 Revision No.: 00180705 CONTENTS Page No. Objective 3 Principle 3 Kit Description 4 Materials Provided 5 Procedure
More informationLINEE GUIDA: VALORI E LIMITI
Ferrara 28 novembre 2014 LINEE GUIDA: VALORI E LIMITI Pierluigi Viale Clinica di Malattie Infettive Policlinico S. Orsola Malpighi EVIDENCE BIASED GERIATRIC MEDICINE Older patients with comorbid conditions
More informationMercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016
Mercy Medical Center Des Moines, Iowa Department of Pathology Microbiology Department Antibiotic Susceptibility January December 2016 These statistics are intended solely as a GUIDE to choosing appropriate
More information